Health and Human Services Secretary Robert F. Kennedy Jr. announced a complete review of the mifepristone abortion pill by the FDA, triggered by a recent study revealing serious safety concerns. The study, conducted by the Ethics & Public Policy Center, found that nearly 11% of women experienced serious adverse events after using the pill. This figure starkly contrasts the FDA's current label, which states a mere 0.5% adverse event rate. Kennedy emphasized the need for a label revision and stricter safety protocols to ensure women's health is prioritized.
The Ethics & Public Policy Center conducted the largest-known study analyzing 865,727 prescribed mifepristone abortions, revealing alarming health risks associated with the pill.
Eleven percent of women using mifepristone experienced serious adverse events, which is significantly higher than the FDA's current reported rate of 0.5%.
Collection
[
|
...
]